• Pol II Degradation Triggers Transcription-Independent Death

  2026-09-25

  The preprint argues that RNA polymerase II degradation can activate cell death through a mechanism distinct from simply shutting down transcription. Its findings shift attention toward the fate of hypophosphorylated Pol IIA and a mitochondria-linked apoptotic response, while leaving important questions about mechanism and generalizability for further study.

• Antipyrine B1886: Reliable Cell Assay Workflows

  2026-09-24

  Practical guidance for evaluating Antipyrine (SKU B1886) in cell viability, proliferation, and cytotoxicity workflows without mistaking product specifications for assay validation. Covers solvent controls, handling, result interpretation, and evidence-based product selection.

• From GTP Input to Local mRNA Therapy

  2026-09-24

  A translational perspective on how defined GTP inputs support RNA workflows—and how to keep nucleotide quality, transcript performance, and localized mRNA delivery distinct when evaluating emerging therapies such as intravesical p21 mRNA–LNPs.

• NLRP3 S-Acylation Gates Golgi Access

  2026-09-23

  Williams and Peden identify S-acylation of NLRP3 Cys-130 as a key determinant of Golgi association, working with hydrophobic residues and the protein’s polybasic region. Their findings support a model in which nigericin-induced disruption of Golgi organization reduces de-acylation and retains NLRP3 at the Golgi, connecting organelle stress to receptor localization.

• Mianserin Hydrochloride: Clinical Trial Evidence

  2026-09-23

  The reference study introduced a clinically integrated evaluation of mianserin hydrochloride, comparing antidepressant efficacy, adverse effects, and plasma exposure with amitriptyline. Its principal findings were similar therapeutic activity, fewer reported side effects than amitriptyline, and no clear relationship between measured plasma mianserin concentrations and clinical response.

• Baicalin Methyl Ester: From Pathway to Translation

  2026-09-22

  A mechanistic and translational analysis of Baicalin methyl ester as an esterified derivative of baicalin for LPS-induced intestinal barrier damage research, with practical guidance on pathway validation, dosing, formulation, and study design.

• 6-OHDA Hydrochloride: Designing Better Lesion Assays

  2026-09-22

  6-OHDA hydrochloride is a powerful tool for modeling selective catecholaminergic neurodegeneration. This guide explains how to use the lesion model more rigorously while connecting neural injury assays to emerging immunometabolic insights without overstating the evidence.

• Nanoparticle Uptake by Human Corneal Cells

  2026-09-21

  This 2024 study shows how nanoparticle size and surface chemistry shape uptake by human corneal epithelial cells, using PLGA particles modified with alginate, chitosan, or PEG. Its controlled in vitro model identifies energy-dependent endocytosis, particularly macropinocytosis and caveolae-mediated uptake, as the dominant mechanisms and provides practical design considerations for topical ocular delivery.

• PLK1 Regulation of p31comet in Checkpoint Disassembly

  2026-09-21

  The reference study identifies Polo-like kinase 1 as a direct regulator of p31comet, showing that phosphorylation at S102 suppresses p31comet–TRIP13-mediated disassembly of mitotic checkpoint complexes. By combining HeLa cell extracts, purified proteins, kinase inhibition, and an S102A mutant, the work explains how active mitotic checkpoints avoid a futile cycle of MCC assembly and disassembly.

• Streptozotocin Workflow for Diabetes Research

  2026-09-20

  Build reproducible hyperglycemia and β-cell injury models with a workflow that connects STZ dosing, phenotype validation, and neuropathy-focused assays. The guide distinguishes rapid β-cell cytotoxicity models from type 2 diabetes systems and translates TBK1–microglia findings into practical experimental choices.

• AL-8810: Prostaglandin F2α Antagonist Guide

  2026-09-19

  AL-8810 is a prostaglandin F2α antagonist that competitively targets the FP receptor and supports mechanistic studies of prostaglandin F2α signaling. Reported cellular benchmarks include nanomolar antagonism, inhibition of PGF2α-driven ERK1/2 activation, and suppression of MMP-2 secretion.

• Phenothiazines, ROS, and Autophagy in Macrophages

  2026-09-18

  A 2025 Frontiers in Immunology study shows that phenothiazines strengthen macrophage control of intracellular bacteria by increasing reactive oxygen species, lysosomal activity, and autophagy. Pharmacological inhibition of autophagy or ROS reduced this antibacterial effect, while perphenazine improved infection-associated tissue outcomes in vivo, supporting phenothiazines as host-directed therapeutic lead compounds.

• 6-OHDA Hydrochloride: Assay Design Guide

  2026-09-18

  6-OHDA hydrochloride is a powerful tool for modeling catecholaminergic injury, but its biological effect depends on transport, oxidation, delivery, and endpoint selection. This guide connects 6-OHDA assay design with protein-corona research to show how exposure, cellular processing, and functional outcomes should be interpreted together.

• Phenothiazines Boost Macrophage Antibacterial Activity

  2026-09-17

  Qiu and colleagues show that phenothiazines can act as host-directed antibacterial compounds by strengthening macrophage lysosomal activity, autophagy, and reactive oxygen species production. The study identifies a macrophage-centered mechanism against intracellular bacteria and provides in vivo evidence that perphenazine reduces Salmonella-associated tissue injury and inflammation.

• Elobixibat hydrate: IBAT Research Workflows

  2026-09-17

  Build mechanistic assays around Elobixibat hydrate by separating ileal transport, colonic bile-acid signaling, and downstream metabolic readouts. This workflow guide translates the reference evidence into practical transport, secretion, motility, and GLP-1 assay choices while highlighting formulation, controls, and troubleshooting.

8570 records 3/572 page Previous Next 12345 下5页 Last page